IGF1 and neoplasm: Notably, the OOC arm pre-randomization contained a greater proportion of patients with higher IGF-1 levels, receiving higher iSRL doses pre-randomization, and a greater proportion of patients with magnetic resonance imaging-evident tumour residuum.31 Of the patients who received iSRL, 47% reported injection site reactions, of which 81% felt that their daily activities were impacted; however, treatment satisfaction and work productivity were not different between the treatment groups.31